Partial pharmacological restoration of FoxO3 activity can attenuate the IPF myofibroblast phenotype in vitro and bleomycin‐induced lung fibrosis in vivo, illuminating a potential therapeutic strategy. This evidence concerns the gene FOXO3 and pulmonary fibrosis.